Analyst Ratings For AtriCure Inc. (NASDAQ:ATRC)

Today, Canaccord Genuity reiterated its Buy rating on AtriCure Inc. (NASDAQ:ATRC) with a price target of $37.00.

There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on AtriCure Inc. (NASDAQ:ATRC) is Buy with a consensus target price of $33.75 per share, a potential 15.19% upside.

Some recent analyst ratings include

• 8/2/2018-Canaccord Genuity Reiterated Rating of Buy.
• 8/2/2018-Needham & Company LLC Reiterated Rating of Buy.
• 6/27/2018-BTIG Research Reiterated Rating of Hold.
• 6/16/2017-Leerink Swann Reiterated Rating of Outperform.
• 3/20/2017-Northland Securities Reiterated Rating of Buy.

Recent Insider Trading Activity For AtriCure Inc. (NASDAQ:ATRC)
AtriCure Inc. (NASDAQ:ATRC) has insider ownership of 10.00% and institutional ownership of 86.69%.

• On 6/14/2018 Mark A Collar, Director, sold 2,090 with an average share price of $25.00 per share and the total transaction amounting to $52,250.00.
• On 5/8/2018 Elizabeth D Krell, Director, sold 10,000 with an average share price of $22.82 per share and the total transaction amounting to $228,200.00.
• On 3/13/2018 Elizabeth D Krell, Director, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
• On 3/1/2018 Regina E Groves, Director, bought 1,000 with an average share price of $17.43 per share and the total transaction amounting to $17,430.00.
• On 2/15/2018 Justin J Noznesky, SVP, sold 4,000 with an average share price of $17.03 per share and the total transaction amounting to $68,120.00.
• On 11/30/2017 M. Andrew Wade, CFO, sold 2,000 with an average share price of $18.41 per share and the total transaction amounting to $36,820.00.
• On 11/8/2017 B Kristine Johnson, Director, bought 1,500 with an average share price of $18.36 per share and the total transaction amounting to $27,540.00.

About AtriCure Inc. (NASDAQ:ATRC)
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Recent Trading Activity for AtriCure Inc. (NASDAQ:ATRC)
Shares of AtriCure Inc. closed the previous trading session at 29.30 up +0.65 2.27% with 183400 shares trading hands.